A new report by visiongain predicts that the overall world antithrombotic and anticoagulant drug market will reach US$24.4 billion in 2015.
The study titled “Antithrombotic Anticoagulant Drugs: World Market 2012-2022” assesses drugs to treat abnormal blood clotting in humans. It predicts that the industry and market for blood thinners will soon recover from the patent expiries of two leading drugs, Plavix and Lovenox. It also says that the overall world antithrombotic treatments market will show a gradual increase in sales revenues to 2022. Supporting that expansion will be increasing disease incidence, prevalence and diagnosis, especially in the developing markets of China and India.
This study forecasts revenues of ten leading drugs in the antithrombotic agents market, including Plavix, Lovenox, Pletal, Fragmin, Asasantin, Arixtra and Aspirin Cardio. The report also predicts revenues of newly launched drugs: Brilinta, Xarelto, Pradaxa and Effient. Analyses and discussions cover activities of Eli Lilly, Boehringer Ingelheim, AstraZeneca, J&J, Bayer, Sanofi, Merck, Eisai, Daiichi Sankyo and other pharmaceutical companies.
In addition to forecasting the overall world market and leading national markets, the work predicts revenue trends for submarkets. It forecasts sales of platelet aggregation inhibitors, heparins, fibrinolytics, vitamin K antagonists, direct thrombin inhibitors and direct factor Xa inhibitors. The report provides revenue values to 2022 at world market, therapeutic class, product and national levels.
The antithrombotic drug market is expanding. Safer and more efficacious drugs are in demand. Also in demand are antidotes to stop excessive bleeding after treatment. This new report discusses market drivers, restraints and opportunities of revenue growth for blood-thinning drugs.